Blackstone Life Sciences invests $250M in Anagram Therapeutics to advance ANG003, a novel oral enzyme therapy for pancreatic insufficiency. Learn more.
Blackstone Life Sciences invests $250M in Anagram Therapeutics to advance ANG003, a novel oral enzyme therapy for pancreatic insufficiency. Learn more.